SCHEMBL20090108

SCHEMBL20090108

S=P(c1ccc2ccccc2c1)(c1ccc2cc(-c3ccc4c5c6ccccc6ccc5c5nc6ccccc6n5c4c3)ccc2c1)c1ccc2cccnc2c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 2/20 0.35
KMT2A Q03164 4/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
BCL2 P10415 1/20 0.34
MAPT P10636 3/20 0.33
MEN1 O00255 2/20 0.33
CYP1A2 P05177 2/20 0.33
CAMKK1 Q8N5S9 2/20 0.33
CAMKK2 Q96RR4 2/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CASP1 P29466 1/20 0.33
CYP2C19 P33261 1/20 0.33
CASP7 P55210 1/20 0.33
POLB P06746 3/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
CYP3A4 P08684 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20090094 0.95 POLB (0.38) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL20090232 0.93 ALDH1A1 (0.33) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL20090085 0.93 HPGD (0.40) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL20090102 0.91 BCL2 (0.36) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL20090080 0.90 HPGD (0.42) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL19960331 0.86 ALDH1A1 (0.34) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL20090091 0.86 NPC1 (0.38) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL20096538 0.85 BCL2 (0.38) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL19960321 0.85 HPGD (0.35) HPGDALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL20090230 0.84 NPC1 (0.36) MAPTCYP1A2CYP2C19POLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10355225-B2 Heterocyclic compound and organic light emitting element comprising same LG CHEM, LTD. (KR) 2019-07-16 US disclosed
US-20180114923-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME LG CHEM, LTD. (KR) 2018-04-26 US disclosed
US-20180114923-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME LG CHEM, LTD. (KR) 2018-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180114923-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME CRY1, CRY2, PER2 HPGD 2982/4885ALDH1A1 750/4885KDM4E 1997/4885
US-10355225-B2 Heterocyclic compound and organic light emitting element comprising same CRY1, CRY2, PER2 HPGD 2982/4885ALDH1A1 750/4885KDM4E 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.